Search Results

• • 36 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16

  Authors:Daniel P. Petrylak, Donna Pauler Ankerst, Caroline S. Jiang, Catherine M. Tangen, Maha H.A. Hussain, Lara, Primo N., Jr.,Jones, Jeffrey A., et al.From:Journal of the National Cancer Institute (Vol. 98, Issue 8) Peer-Reviewed

  Apr. 19, 2006338 words Author abstract, Cli... 60L

   Abstract Only

• Long-term consequences of finasteride vs placebo in the prostate cancer prevention trial

  Authors:Joseph M. Unger, Cathee Till, Ian M. Thompson, Jr., Catherine M. Tangen, Phyllis J. Goodman, Jason D. Wright, et al.From:Journal of the National Cancer Institute (Vol. 108, Issue 12) Peer-Reviewed

  Dec. 13, 2016281 words Author abstract, Rep...

   Abstract Only

• Frailty in Older Adults: Evidence for a Phenotype

  Authors:Linda P. Fried, Catherine M. Tangen, Jeremy Walston, Anne B. Newman, Calvin Hirsch, John Gottdiener, et al.From:The Journals of Gerontology, Series APeer-Reviewed

  Mar. 2001443 words Article

   Abstract Only

• Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710

  Authors:John P. Christodouleas, Brian C. Baumann, Jiwei He, Wei-Ting Hwang, Kai N. Tucker, Justin E. Bekelman, et al.From:Cancer (Vol. 120, Issue 8) Peer-Reviewed

  Apr. 15, 2014 Report

   Citation Only

• Finasteride and high-grade prostate cancer in The Prostate Cancer Prevention Trial

  Authors:M. Scott Lucia, Jonathan I. Epstein, Phyllis J. Goodman, Amy K. Darke, Victor E. Reuter, Francisco Civantos, et al.From:Journal of the National Cancer Institute (Vol. 99, Issue 18) Peer-Reviewed

  Sept. 19, 2007403 words Clinical report

   Abstract Only

• Effects of beam collimation on image quality

  Authors:Charlotte A. Peterson, Sally M. Mauriello, Vickie P. Overman, Enrique Platin, and Catherine M. TangenFrom:Journal of Dental Hygiene (Vol. 71, Issue 2) Peer-Reviewed

  March-April 19974,752 words Article Abstract Purpose. The purpose of this study was to determine the effect of three film-speed/collimator combinations on image quality, based on reviewer preference and diagnostic quality, based on caries detection....

• Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial

  Authors:Edward M. Messing, Catherine M. Tangen, Seth P. Lerner, Deepak M. Sahasrabudhe, Theresa M. Koppie, Wood. David P. Jr., et al.From:JAMA, The Journal of the American Medical Association (Vol. 319, Issue 18) Peer-Reviewed

  May 8, 201847 words Article

   Citation Only

• Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group Trial (SWOG 9426)

  Authors:A. Oliver Sartor, Catherine M. Tangen, Maha H.A. Hussain, Mario A. Eisenberger, Minoti Parab, Joseph A. Fontana, et al.From:Cancer (Vol. 112, Issue 11) Peer-Reviewed

  June 1, 2008 Clinical report

   Citation Only

• Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies

  Authors:Tomasz M. Beer, Catherine M. Tangen, Craig R. Nichols, Kim A. Margolin, Robert Dreicer, William T. Stephenson, et al.From:Cancer (Vol. 106, Issue 12) Peer-Reviewed

  June 15, 2006 Article

   Citation Only

• Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid: a Southwest Oncology Group study

  Authors:Ronald M. Bukowski, Catherine M. Tangen, Robert F. Peterson, Sarah A. Taylor, John J. Rinehart, Harmon J. Eyre, et al.From:Cancer (Vol. 73, Issue 5) Peer-Reviewed

  Mar. 1, 1994150 words Article

   Abstract Only

• Effect of finasteride on the sensitivity of PSA for detecting prostate cancer

  Authors:Ian M. Thompson, Chen Chi, Donna Pauler Ankerst, Phyllis J. Goodman, Catherine M. Tangen, Scott M. Lippman, et al.From:Journal of the National Cancer Institute (Vol. 98, Issue 16) Peer-Reviewed

  Aug. 16, 2006354 words Author abstract 60L

   Abstract Only

• Prostate cancer screening comes of age

  Authors:Ian M. Thompson and Catherine M. TangenFrom:The Lancet (Vol. 384, Issue 9959) Peer-Reviewed

  Dec. 6, 201448 words Article

   Abstract Only

• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

  Authors:H. Barton Grossman, Ronald B. Natale, Catherine M. Tangen, V.O. Speights, Nicholas J. Vogelzang, Donald L. Trump, et al.From:The New England Journal of Medicine (Vol. 349, Issue 9) Peer-Reviewed

  Aug. 28, 200352 words Article

   Citation Only

• Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial

  Authors:Ian M. Thompson, Jr. and Catherine M. TangenFrom:JAMA, The Journal of the American Medical Association (Vol. 296, Issue 19) Peer-Reviewed

  Nov. 15, 200664 words Clinical report

   Citation Only

• Plasma phospholipid fatty acids and prostate cancer risk in the SELECT Trial

  Authors:Theodore M. Brasky, Amy K. Darke, Xiaoling Song, Catherine M. Tangen, Phyllis J. Goodman, Ian M. Thompson, et al.From:Journal of the National Cancer Institute (Vol. 105, Issue 15) Peer-Reviewed

  Aug. 7, 2013282 words Author abstract, Rep...

   Abstract Only

• The influence of finasteride on the development of prostate cancer

  Authors:Ian M. Thompson, Phyllis J. Goodman, Catherine M. Tangen, M. Scott Lucia, Gary J. Miller, Leslie G. Ford, et al.From:The New England Journal of Medicine (Vol. 349, Issue 3) Peer-Reviewed

  July 17, 200380 words Article

   Citation Only

• Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial

  Authors:Zhihong Gong, Alan R. Kristal, Jeannette M. Schenk, Catherine M. Tangen, Phyllis J. Goodman, and Ian M. ThompsonFrom:Cancer (Vol. 115, Issue 16) Peer-Reviewed

  Aug. 15, 2009 Clinical report

   Citation Only

• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

  Authors:Daniel P. Petrylak, Maha H.A. Hussain, Catherine M. Tangen, Primo N. Jr. Lara, Mary Ellen Taplin, Jeffrey A. Jones, et al.From:The New England Journal of Medicine (Vol. 351, Issue 15) Peer-Reviewed

  Oct. 7, 200435 words Article

   Citation Only

• Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial

  Authors:Douglas K. Price, Cindy H. Chau, Cathee Till, Phyllis J. Goodman, Robin J. Leach, Teresa L. Johnson-Pais, et al.From:Cancer (Vol. 122, Issue 15) Peer-Reviewed

  Aug. 1, 2016 Article

   Citation Only

• level <= 4.0 ng per milliliter

  Authors:Ian M Thompson, Donna K Pauler, Phyllis J. Goodman, Catherine M Tangen, M. Scott Lucia, Howard L. Parnes, et al.From:The New England Journal of Medicine (Vol. 350, Issue 22) Peer-Reviewed

  May 27, 200467 words Article

   Citation Only